Adrian Newman-Tancredi
is co-founder and
Chief Scientific Officer
Neurolixis Inc.



Adrian Newman-Tancredi will be chairing a session at the World Orphan Drug Congress in Brussels, Belgium, on 12th to 14th October 2014. Dr. Newman-Tancredi has been invited to chair...Read More
Having co-founded Neurolixis Inc. in 2011, Adrian Newman-Tancredi now has an additional role as President and CEO of its subsidiary in France, Neurolixis SAS. The latter was created in...Read More
Adrian Newman-Tancredi is PI of a supplementary research grant that has been awarded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Neurolixis Inc. Adrian is...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.